Propanc Biopharma explains how PRP might affect pancreatic cancer

Propanc Biopharma described its PRP proenzyme candidate and said it plans to begin Phase I/II clinical trials in 2026; the article notes the FDA granted PRP Orphan Drug Designation in 2017.

Propanc Biopharma released an update on its pancreatic proenzyme candidate called PRP and its planned clinical path. The company describes PRP as a proprietary mixture of pancreatic proenzymes given intravenously and reports preclinical findings that the agent may target cancer stem cells and affect processes linked to metastasis and resistance. The article mentions the FDA granted PRP Orphan Drug Designation in 2017 and that Propanc is a pre-revenue company with a Nasdaq listing. Key points: - PRP is described as a proprietary mixture of pancreatic proenzymes administered intravenously and is hypothesized to target cancer stem cells and modify cellular programs linked to metastasis. - The U.S. Food and Drug Administration granted Orphan Drug Designation to PRP for pancreatic cancer in 2017, as reported in the article. - The company reports plans to initiate Phase I/II clinical trials in 2026, beginning with dose-finding studies and moving to proof-of-concept studies in pancreatic and other cancers. Summary: The company presents PRP as an early-stage candidate with a mechanism different from standard therapies, while noting the historical challenges in translating preclinical results into clinical benefit. The next stated step is initiation of Phase I/II trials in 2026; broader outcomes and impacts are undetermined at this time.